Viking Therapeutics: Analysts See Price Target at $94 – Stock Trading at $31
By Redaktion aktie.com
This article was created with the help of artificial intelligence.
Key Takeaways
- Viking Therapeutics closed at $30.90 on August 20, 2026, a gain of 0.49 percent.
- Analysts set an average price target of $93.60, with the highest forecast at $101 (as of July 9, 2026).
- Of 24 analysts, 23 recommend buying the stock, one advises holding, and no sell recommendations are present.
- Loss per share is -$4.66; the company generates no revenue during the clinical phase.
- The RSI indicator stood at 57.48 on August 19, signaling moderate positive price momentum.
Viking Therapeutics traded at $30.90 on August 20, 2026, gaining $0.15 compared to the previous day, representing an increase of 0.49 percent. The U.S. biotechnology company achieved a market capitalization of $3.8 billion.
Analyst Consensus: Strong Buy Signal
The average analyst price target as of July 9, 2026 is $93.60. The range extends from $83 as the lowest to $101 as the highest target, with a median price target of $95. Of a total of 24 analysts covering the stock, one analyst rates it as Strong Buy, 22 analysts recommend buying, and only one analyst recommends holding. No sell recommendations are present.
The midpoint price target implies upside potential of approximately 203 percent from the current price. The positive analyst assessment reflects expectations for the company's pipeline, particularly the dual GLP-1/GIP receptor agonist VK2735 for the treatment of obesity.
Technical Indicators in Neutral Range
The Relative Strength Index (RSI) – a momentum indicator that shows overbought or oversold conditions – was at 57.48 on August 19, 2026. An RSI value above 50 indicates positive price momentum without entering the overbought range above 70. In the preceding weeks, the RSI moved predominantly between 35 and 48, indicating a prior weakness phase.
The stock's 52-week high stands at $43.15, with a low of $22.96. The beta coefficient of 0.61 signals comparatively low volatility relative to the broader market – the stock reacts less strongly to general market movements than average.
Loss Per Share in Negative Earnings Position
Viking Therapeutics is a company without revenue in the clinical development phase. The loss per share (EPS) is -$4.66. A price-to-earnings ratio (P/E) cannot be calculated due to absent earnings. The price-to-book ratio (P/B) stands at 6.22 – investors are thus paying 6.22 times the book value per share.
The average trading volume for the previous period is stated as 1.64 million shares. On August 20, 2026, the actual volume was significantly lower at approximately 7,100 shares, indicating a rather quiet trading day.
About Viking Therapeutics
Viking Therapeutics is a publicly traded biotechnology company headquartered in the U.S. that has been traded on the stock exchange since April 2015. The focus is on developing therapies for metabolic and endocrine diseases. The lead candidate VK2735 is a dual GLP-1/GIP receptor agonist currently in clinical trials for the treatment of obesity. GLP-1-based medications have received considerable market attention in recent years through the successes of competitors such as Novo Nordisk and Eli Lilly.
The company has generated no revenue to date and finances itself through capital market measures. Investor expectations are primarily focused on clinical trial results and potential partnerships or acquisitions by larger pharmaceutical companies.